Cargando…

Characteristics of HIV-1 gp120 molecules that bind ancestor, intermediate and mature forms of VRC01-like antibodies

Detalles Bibliográficos
Autores principales:	Joyce, M, Zhang, B, Zhou, T, Moquin, S, Wu, X, Louder, M, Zhang, Z, Georgiev, I, Zhu, J, Shapiro, L, Mascola, JR, Nabel, GJ, Kwong, PD
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2012
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3442057/ http://dx.doi.org/10.1186/1742-4690-9-S2-P68

Ejemplares similares

Structure-guided modification and optimization of antibody VRC07
por: Kwon, Y, et al.
Publicado: (2012)

Partial germline reversions can increase VRC07 potency and breadth
por: Rudicell, RS, et al.
Publicado: (2012)

Deep sequencing with longitudinal sampling of a VRC01-like-antibody response in a chronically infected individual
por: Zhang, Z, et al.
Publicado: (2012)

Hyperglycosylated resurfaced stabilized GP120 core as an immunogen elicits antibodies targeted at the CD4-binding site
por: Dai, K, et al.
Publicado: (2012)

Engineered gp120 immunogens that elicit VRC01-like antibodies by vaccination
por: Mata-Fink, J, et al.
Publicado: (2012)

Transforming epitope-specific gp120 monomer-based probes into immunogens with N-linked glycan masking
por: Chuang, G, et al.
Publicado: (2012)

NMR spectroscopy of HIV-1 gp120 outer domain
por: Sastry, M, et al.
Publicado: (2012)

Germline VRC01 antibody recognition of a modified clade C HIV-1 envelope trimer and a glycosylated HIV-1 gp120 core
por: Borst, Andrew J, et al.
Publicado: (2018)

Structural definition for a new modality of broad and potent antibody neutralization at the CD4-binding site on HIV-1 gp120
por: Zhou, T, et al.
Publicado: (2012)

Prediction of VRC01 neutralization sensitivity by HIV-1 gp160 sequence features
por: Magaret, Craig A., et al.
Publicado: (2019)

Inference of the HIV-1 VRC01 Antibody Lineage Unmutated Common Ancestor Reveals Alternative Pathways to Overcome a Key Glycan Barrier
por: Bonsignori, Mattia, et al.
Publicado: (2018)

P14-10. Comparable immunogenicity of VRC DNA and rAd5 HIV-1 vaccines delivered by intramuscular, subcutaneous and intradermal routes in healthy adults (VRC 011)
por: Ledgerwood, JE, et al.
Publicado: (2009)

P04-38. Crystal structure of gp120 in complex with the CD4-binding-site antibody b13 suggests precise targeting is needed for neutralization
por: Zhou, T, et al.
Publicado: (2009)

Adjuvants influence the maturation of VRC01-like antibodies during immunization
por: Knudsen, Maria L., et al.
Publicado: (2022)

Characterization of a vaccine-elicited human antibody with sequence homology to VRC01-class antibodies that binds the C1C2 gp120 domain
por: Gray, Matthew D., et al.
Publicado: (2022)

A matrix of structure-based designs yields improved VRC01-class antibodies for HIV-1 therapy and prevention
por: Kwon, Young D., et al.
Publicado: (2021)

Mammalian production of an isotopically enriched outer domain of the HIV-1 gp120 glycoprotein for NMR spectroscopy
por: Sastry, Mallika, et al.
Publicado: (2011)

Improved pharmacokinetics of HIV-neutralizing VRC01-class antibodies achieved by reduction of net positive charge on variable domain
por: Kwon, Young D., et al.
Publicado: (2023)

Modeling cumulative overall prevention efficacy for the VRC01 phase 2b efficacy trials
por: Huang, Yunda, et al.
Publicado: (2018)

Characterizing the fitness cost of viral escape from the HIV-1 broadly neutralizing monoclonal antibody VRC01
por: Lynch, RM, et al.
Publicado: (2012)

A short segment in the HIV-1 gp120 V1/V2 region is a major determinant of neutralization resistance to PG9-like antibodies
por: Doria-Rose, NA, et al.
Publicado: (2012)

Pharmacokinetic serum concentrations of VRC01 correlate with prevention of HIV-1 acquisition
por: Seaton, Kelly E., et al.
Publicado: (2023)

P13-01. Crystal structure and function of a monoclonal antibody against primate CD4 that blocks HIV/SIV infection
por: Pegu, A, et al.
Publicado: (2009)

Phase I Randomized Clinical Trial of VRC DNA and rAd5 HIV-1 Vaccine Delivery by Intramuscular (IM), Subcutaneous (SC) and Intradermal (ID) Administration (VRC 011)
por: Enama, Mary E., et al.
Publicado: (2014)

Correction: HIV-1 envelope glycan modifications that permit neutralization by germline-reverted VRC01-class broadly neutralizing antibodies
por: LaBranche, Celia C., et al.
Publicado: (2019)

Neutralizing antibody VRC01 failed to select for HIV-1 mutations upon viral rebound
por: Cale, Evan M., et al.
Publicado: (2020)

Delayed vaginal SHIV infection in VRC01 and anti-α4β7 treated rhesus macaques
por: Calenda, Giulia, et al.
Publicado: (2019)

Structure-Based Stabilization of HIV-1 gp120 Enhances Humoral Immune Responses to the Induced Co-Receptor Binding Site
por: Dey, Barna, et al.
Publicado: (2009)

454 pyrosequencing and bioinformatics analysis of the lineage of the broad and potent gp41-directed antibody 10e8
por: Ofek, G, et al.
Publicado: (2012)

Pharmacokinetics and predicted neutralisation coverage of VRC01 in HIV-uninfected participants of the Antibody Mediated Prevention (AMP) trials
por: Huang, Yunda, et al.
Publicado: (2021)

HIV-1 envelope glycan modifications that permit neutralization by germline-reverted VRC01-class broadly neutralizing antibodies
por: LaBranche, Celia C., et al.
Publicado: (2018)

Rapid and Focused Maturation of a VRC01-Class HIV Broadly Neutralizing Antibody Lineage Involves Both Binding and Accommodation of the N276-Glycan
por: Umotoy, Jeffrey, et al.
Publicado: (2019)

Selection of Peptide Mimics of HIV-1 Epitope Recognized by Neutralizing Antibody VRC01
por: Chikaev, Anton N., et al.
Publicado: (2015)

Overcoming Steric Restrictions of VRC01 HIV-1 Neutralizing Antibodies through Immunization
por: Parks, K. Rachael, et al.
Publicado: (2019)

Structural definition of a conserved neutralization epitope on HIV-1 gp120
por: Zhou, Tongqing, et al.
Publicado: (2007)

Prediction of serum HIV-1 neutralization titers of VRC01 in HIV-uninfected Antibody Mediated Prevention (AMP) trial participants
por: Huang, Yunda, et al.
Publicado: (2021)

Development of a VRC01-class germline targeting immunogen derived from anti-idiotypic antibodies
por: Seydoux, Emilie, et al.
Publicado: (2021)

Germline-targeting HIV-1 Env vaccination induces VRC01-class antibodies with rare insertions
por: Caniels, Tom G., et al.
Publicado: (2023)

Neutralization profiles of HIV-1 viruses from the VRC01 Antibody Mediated Prevention (AMP) trials
por: Mkhize, Nonhlanhla N., et al.
Publicado: (2023)

B cells expressing authentic naive human VRC01-class BCRs can be recruited to germinal centers and affinity mature in multiple independent mouse models
por: Huang, Deli, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_0fkpbmla1dilrqk467tniv1kbq